Pirfenex 600mg Tablet

Pirfenex 600mg Tablet is an oral antifibrotic medication with Pirfenidone as an active ingredient. It is used to treat idiopathic pulmonary fibrosis as prescribed by the doctor.

This medicine works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.​

• Treatment of Idiopathic pulmonary fibrosis

Most side effects of Pirfenex 600mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Common side effects include:

• Headache
• Dizziness
• Insomnia (difficulty in sleeping)
• Sinus inflammation
• Tiredness
• Photosensitivity
• Loss of appetite
• Weight loss
• Upper respiratory tract infection

• The dosage and duration of the Pirfenex 600mg Tablet are decided by the doctor based on the severity of the infection and other health factors. This tablet can be taken with or without food but take it at the same time everyday for better results.
• Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​​
  

• Pirfenex 600mg Tablet is an oral antifibrotic medication with Pirfenidone as an active ingredient.
• This medicine works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath.​​
  

• Nicod, L. P. (1999). Pirfenidone in idiopathic pulmonary fibrosis. The Lancet, 354(9175), 268-269. https://pubmed.ncbi.nlm.nih.gov/10440298/
• Hanta, I., Cilli, A., & Sevinc, C. (2019). The effectiveness, safety, and tolerability of Pirfenidone in idiopathic pulmonary fibrosis: a retrospective study. Advances in Therapy, 36(5), 1126-1131. https://pubmed.ncbi.nlm.nih.gov/30900199/
• Aravena, C., Labarca, G., Venegas, C., Arenas, A., & Rada, G. (2015). Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PloS one, 10(8), e0136160.https://pubmed.ncbi.nlm.nih.gov/26308723/
• Takeda, Y., Tsujino, K., Kijima, T., & Kumanogoh, A. (2014). Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient preference and adherence, 361-370. https://pubmed.ncbi.nlm.nih.gov/24711695/
• Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., ... & Pirfenidone Clinical Study Group in Japan. (2010). Pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal, 35(4), 821-829.